HK1200361A1 - Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication - Google Patents
Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication Download PDFInfo
- Publication number
- HK1200361A1 HK1200361A1 HK15101053.5A HK15101053A HK1200361A1 HK 1200361 A1 HK1200361 A1 HK 1200361A1 HK 15101053 A HK15101053 A HK 15101053A HK 1200361 A1 HK1200361 A1 HK 1200361A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyridin
- pyrimidin
- thiazol
- amine
- ylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542907P | 2011-10-04 | 2011-10-04 | |
| US61/542,907 | 2011-10-04 | ||
| PCT/US2012/058674 WO2013052613A1 (en) | 2011-10-04 | 2012-10-04 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1200361A1 true HK1200361A1 (en) | 2015-08-07 |
Family
ID=48044139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15101053.5A HK1200361A1 (en) | 2011-10-04 | 2012-10-04 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20140249154A1 (enExample) |
| EP (1) | EP2763674A4 (enExample) |
| JP (2) | JP6240078B2 (enExample) |
| KR (1) | KR20140071472A (enExample) |
| CN (1) | CN103957908A (enExample) |
| AU (1) | AU2012318670B2 (enExample) |
| BR (1) | BR112014007963A2 (enExample) |
| CA (1) | CA2850779A1 (enExample) |
| HK (1) | HK1200361A1 (enExample) |
| IL (1) | IL231923A0 (enExample) |
| PH (1) | PH12014500724A1 (enExample) |
| SG (1) | SG11201401207XA (enExample) |
| WO (1) | WO2013052613A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9582896B2 (en) * | 2011-09-02 | 2017-02-28 | Qualcomm Incorporated | Line tracking with automatic model initialization by graph matching and cycle detection |
| AU2013343291B2 (en) | 2012-11-07 | 2018-05-10 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors and their use in therapy |
| US20160031874A1 (en) | 2013-03-13 | 2016-02-04 | The Broad Institute, Inc. | Substituted aminothiazoles for the treatment of tuberculosis |
| EP2994465B1 (en) | 2013-05-10 | 2018-08-15 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors |
| WO2016046759A2 (en) | 2014-09-22 | 2016-03-31 | Fratagene Therapeutics Ltd. | Compositions and methods for treating friedreich's ataxia |
| US10442779B2 (en) | 2014-09-22 | 2019-10-15 | Fratagene Therapeutics S.R.L. | Compositions and methods for treating Friedreich's ataxia |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| CA2984252A1 (en) * | 2015-04-29 | 2016-11-03 | Foresight Biotherapeutics, Inc. | Therapeutic combinations of antiviral and anti-inflammatory therapies |
| CN105524056A (zh) * | 2016-01-05 | 2016-04-27 | 中山大学肿瘤防治中心 | 一种氨基噻唑化合物及其制备方法和应用 |
| US10913734B2 (en) * | 2016-07-11 | 2021-02-09 | Baruch S. Blumberg Institute | Substituted aminothiazoles |
| IL271491B2 (en) * | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| US10426775B2 (en) | 2017-09-11 | 2019-10-01 | Fratagene Therapeutics Srl | Methods for treating Friedreich's ataxia with etravirine |
| KR20230092972A (ko) * | 2020-10-23 | 2023-06-26 | 셀진 코포레이션 | 연충 감염 및 질병의 치료를 위한 헤테로환식 화합물 및 이들의 용도 |
| WO2025017207A1 (en) | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
| WO2025151517A1 (en) * | 2024-01-08 | 2025-07-17 | Wavebreak Therapeutics Limited | Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003525291A (ja) * | 2000-03-01 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ２，４−二置換チアゾリル誘導体 |
| MXPA04001399A (es) * | 2001-08-13 | 2004-05-27 | Janssen Pharmaceutica Nv | Derivados de tiazolilo 2-amino-4,5-trisustituidos. |
| WO2005097767A1 (en) * | 2004-03-30 | 2005-10-20 | Merck & Co., Inc. | 2-aminothiazole compounds useful as aspartyl protease inhibitors |
| WO2005099673A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycylic thiazoles as potassium ion channel modulators |
| KR20080019213A (ko) * | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| CA2645072A1 (en) * | 2006-03-08 | 2007-09-13 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole derivatives with anti-hcv activity |
| US9034574B2 (en) * | 2006-12-27 | 2015-05-19 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| WO2009114552A1 (en) * | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| CA2793276A1 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
-
2012
- 2012-10-04 WO PCT/US2012/058674 patent/WO2013052613A1/en not_active Ceased
- 2012-10-04 PH PH1/2014/500724A patent/PH12014500724A1/en unknown
- 2012-10-04 EP EP12838333.8A patent/EP2763674A4/en not_active Withdrawn
- 2012-10-04 SG SG11201401207XA patent/SG11201401207XA/en unknown
- 2012-10-04 JP JP2014534680A patent/JP6240078B2/ja not_active Expired - Fee Related
- 2012-10-04 CA CA2850779A patent/CA2850779A1/en not_active Abandoned
- 2012-10-04 US US14/349,014 patent/US20140249154A1/en not_active Abandoned
- 2012-10-04 KR KR1020147011691A patent/KR20140071472A/ko not_active Ceased
- 2012-10-04 AU AU2012318670A patent/AU2012318670B2/en not_active Ceased
- 2012-10-04 CN CN201280059490.1A patent/CN103957908A/zh active Pending
- 2012-10-04 BR BR112014007963A patent/BR112014007963A2/pt not_active IP Right Cessation
- 2012-10-04 HK HK15101053.5A patent/HK1200361A1/xx unknown
-
2014
- 2014-04-03 IL IL231923A patent/IL231923A0/en unknown
-
2016
- 2016-09-07 US US15/258,393 patent/US10087173B2/en not_active Expired - Fee Related
-
2017
- 2017-04-13 JP JP2017079817A patent/JP2017149753A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20170066758A1 (en) | 2017-03-09 |
| AU2012318670B2 (en) | 2017-09-07 |
| WO2013052613A1 (en) | 2013-04-11 |
| EP2763674A1 (en) | 2014-08-13 |
| CA2850779A1 (en) | 2013-04-11 |
| US10087173B2 (en) | 2018-10-02 |
| US20140249154A1 (en) | 2014-09-04 |
| PH12014500724A1 (en) | 2014-05-19 |
| IL231923A0 (en) | 2014-05-28 |
| BR112014007963A2 (pt) | 2013-04-11 |
| JP2017149753A (ja) | 2017-08-31 |
| KR20140071472A (ko) | 2014-06-11 |
| JP6240078B2 (ja) | 2017-11-29 |
| EP2763674A4 (en) | 2015-04-29 |
| CN103957908A (zh) | 2014-07-30 |
| JP2014528450A (ja) | 2014-10-27 |
| SG11201401207XA (en) | 2014-05-29 |
| AU2012318670A1 (en) | 2014-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200361A1 (en) | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | |
| AU2013226013B2 (en) | Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation and Their Method of Use | |
| CN110475775B (zh) | 4-吡啶酮化合物或其盐、包含4-吡啶酮化合物的药物组合物及剂 | |
| CN110036005B (zh) | 酰胺衍生物及其在药物中的应用 | |
| CN109748915B (zh) | 流感病毒复制抑制剂及其使用方法和用途 | |
| KR102554019B1 (ko) | 인플루엔자 바이러스 복제의 억제제 및 이의 용도 | |
| KR20170029602A (ko) | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 피리다존 및 트라이아진온 | |
| CA3173354A1 (en) | A 2,3-dihydrofuro[2,3-c]pyridine-3-carboxamide compound and its antiviral use | |
| EP3679029A1 (en) | Imidazolidine compounds | |
| CN107793409B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| US10913734B2 (en) | Substituted aminothiazoles | |
| WO2020221280A1 (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN114805362B (zh) | 新型酰胺吡咯类化合物及其在药物中的用途 | |
| CN114075206B (zh) | 新型稠环类化合物及其在药物中的应用 | |
| CN114685514A (zh) | 新型酰胺吡咯类化合物及其在药物中的应用 | |
| WO2023230249A1 (en) | Novel hepatoselective polyadenylating polymerases inhibitors and their method of use | |
| HK40104934A (zh) | 新型肝选择性聚腺苷酸化聚合酶抑制剂及其使用方法 | |
| CN119176804A (zh) | 酰胺吡咯类化合物及其在药物中的应用 | |
| CN121378245A (zh) | 嘧啶并芳香环类化合物及其在药物中的应用 | |
| CN121064198A (zh) | 嘧啶并芳香环类化合物及其在药物中的应用 | |
| CN118666737A (zh) | 苯酚衍生物、包含其的药物组合物及其制备方法和用途 | |
| HK40010596A (en) | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including the same |